Endpoints News· Kyle LaHucik·· 2 小时前AI 评分42
Karyopharm 拟与曾试图收购 bluebird 的 Ayrmid 合并，并将走破产程序
Karyopharm plans to merge with Ayrmid, the company that tried buying bluebird
AI 导读
商业化阶段血液肿瘤生物科技公司 Karyopharm 在剩余选择有限的情况下将走破产程序，并计划与另一家血液领域药企 Ayrmid 合并。Ayrmid 此前曾试图收购 bluebird。
正文 · 原文
With few options remaining, a commercial-stage blood cancer biotech will go through a bankruptcy process and plans to merge with another drugmaker in the blood …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源：Endpoints News · endpoints.news